Literature DB >> 9428833

Diagnosis of hemochromatosis probands in a community hospital.

J C Barton1, N H Barton, T J Alford.   

Abstract

PURPOSE: To evaluate factors that lead to the diagnosis of hemochromatosis probands in a community hospital, including education of physicians about hemochromatosis and iron overload, specialty of physicians, diagnostic indicators of hemochromatosis, and clinical manifestations of hemochromatosis probands. PATIENTS AND METHODS: We conducted a hemochromatosis education program for health care personnel associated with a community hospital and the public during 1990 to 1994. Data on physicians who diagnosed probands, diagnostic indicators of hemochromatosis, and manifestations of hemochromatosis and associated illnesses were tabulated. Iron grades of all hospital liver biopsy specimens obtained from Caucasian subjects during 1990 to 1994 were also analyzed.
RESULTS: We identified 162 hemochromatosis probands; 66.7% were diagnosed by physicians who participated in our education program. Primary care and internal medicine subspecialty physicians diagnosed 66.7% and 29.6% of probands, respectively, based on elevated serum iron parameters and hepatic enzyme concentrations (51.9% and 36.4% of probands, respectively). Iron overload occurred in 90.7%, and was associated with clinical manifestations in most. Of 844 hospital liver biopsy specimens from Caucasians, 8.5% had increased iron grades; 4.6% represented hemochromatosis.
CONCLUSIONS: Physicians with current education readily diagnose hemochromatosis probands during routine health care delivery, but most probands identified in this manner have iron overload. Our results suggest that community physicians and hospitals could contribute substantially to hemochromatosis screening programs, permitting detection of more homozygotes before the development of iron overload.

Entities:  

Mesh:

Year:  1997        PMID: 9428833     DOI: 10.1016/s0002-9343(97)00276-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  Population screening for hemochromatosis: has the time finally come?

Authors:  J C Barton; R T Acton
Journal:  Curr Gastroenterol Rep       Date:  2000-02

2.  Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: the HEIRS study.

Authors:  James C Barton; Catherine Leiendecker-Foster; David M Reboussin; Paul C Adams; Ronald T Acton; John H Eckfeldt
Journal:  Thyroid       Date:  2008-08       Impact factor: 6.568

3.  Total blood lymphocyte counts in hemochromatosis probands with HFE C282Y homozygosity: relationship to severity of iron overload and HLA-A and -B alleles and haplotypes.

Authors:  James C Barton; Ronald T Acton; Howard W Wiener; Rodney Cp Go
Journal:  BMC Blood Disord       Date:  2005-07-25

Review 4.  Diabetes in HFE Hemochromatosis.

Authors:  James C Barton; Ronald T Acton
Journal:  J Diabetes Res       Date:  2017-02-26       Impact factor: 4.011

Review 5.  Abdominal pain and cirrhosis at diagnosis of hemochromatosis: Analysis of 219 referred probands with HFE p.C282Y homozygosity and a literature review.

Authors:  James C Barton; J Clayborn Barton; Neha Patel; Gordon D McLaren
Journal:  PLoS One       Date:  2021-12-21       Impact factor: 3.240

6.  Effect of Native American ancestry on iron-related phenotypes of Alabama hemochromatosis probands with HFE C282Y homozygosity.

Authors:  James C Barton; Ellen H Barton; Ronald T Acton
Journal:  BMC Med Genet       Date:  2006-03-13       Impact factor: 2.103

7.  HFE C282Y and H63D in adults with malignancies in a community medical oncology practice.

Authors:  James C Barton; Luigi F Bertoli; Ronald T Acton
Journal:  BMC Cancer       Date:  2004-02-10       Impact factor: 4.430

8.  Autoimmune Conditions in 235 Hemochromatosis Probands with HFE C282Y Homozygosity and Their First-Degree Relatives.

Authors:  James C Barton; J Clayborn Barton
Journal:  J Immunol Res       Date:  2015-10-04       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.